Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 5.8% – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) rose 5.8% during trading on Monday . The company traded as high as $28.49 and last traded at $28.4420. Approximately 689,063 shares changed hands during trading, a decline of 68% from the average daily volume of 2,157,991 shares. The stock had previously closed at $26.89.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CAPR. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday. Industrial Alliance Securities set a $48.00 target price on shares of Capricor Therapeutics in a research report on Wednesday. Oppenheimer boosted their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research report on Monday. Maxim Group raised their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Up 10.6%

The firm has a market capitalization of $1.36 billion, a PE ratio of -16.60 and a beta of 0.62. The company has a 50-day moving average of $7.59 and a 200 day moving average of $8.22.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.54). As a group, equities analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its position in Capricor Therapeutics by 6.8% in the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock valued at $9,565,000 after purchasing an additional 61,701 shares during the last quarter. Woodline Partners LP increased its stake in shares of Capricor Therapeutics by 15.8% in the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock worth $6,921,000 after buying an additional 99,384 shares during the period. Pier Capital LLC increased its stake in shares of Capricor Therapeutics by 35.0% in the third quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock worth $3,580,000 after buying an additional 128,837 shares during the period. Octagon Capital Advisors LP bought a new stake in Capricor Therapeutics during the 1st quarter valued at $4,270,000. Finally, Goldman Sachs Group Inc. boosted its position in Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after buying an additional 116,373 shares during the period. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.